Could a Three-Drug cocktail wipe out aggressive breast cancer before surgery?
NCT ID NCT05498896
First seen May 21, 2026 · Last updated May 23, 2026 · Updated 1 time
Summary
This study tests whether adding a drug called ipatasertib to standard chemotherapy and immunotherapy helps shrink or eliminate aggressive triple-negative breast tumors before surgery. About 146 women with newly diagnosed, high-risk breast cancer will participate. The main goal is to see if the combination leads to no cancer remaining in the breast tissue at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts Health NHS Trust
London, United Kingdom
Conditions
Explore the condition pages connected to this study.